Oslo, Norway

Gemvax as

Calculating rank
USPTO Granted Patents = 10

% Expired Patents = 60.0



Forward Citations = 206

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Jon Amund Eriksen (10 out of 17 patents)

silverMedal Gustav Gaudernack (9 out of 21 patents)

bronzeMedal Mona Møller (7 out of 7 patents)

4.  Marianne Klemp Gjertsen (6 out of 6 patents)

5.  Ingvil Sæterdal (3 out of 3 patents)

6.  Mona Moller (2 out of 2 patents)

7.  Ingvil Saeterdal (2 out of 2 patents)

8.  Stein Sæbøe-Larssen (2 out of 2 patents)

9.  Stein Sæbøe-Larsen (2 out of 2 patents)

10.  Stein Sæøe-Larssen (1 out of 1 patent)

11.  Gustay Gaudernack (1 out of 1 patent)

12.  Mona Møller (1 out of 1 patent)

13.  Ingvil Sæterdal (1 out of 1 patent)

14.  Stein Saeboe-Larssen (0 patent)

15.  Mona Moeller (0 patent)


10 patents:

Company Overview
Gemvax AS is a biotechnology company based in Oslo, Norway, focused on the development of innovative therapies for cancer treatment. The organization specializes in harnessing advanced technologies to create novel immunotherapies that aim to enhance the body's natural ability to fight tumors. With a commitment to research and development, Gemvax AS is dedicated to addressing unmet medical needs in oncology, leveraging its expertise in biopharmaceuticals to contribute to the evolving landscape of cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

10 Patents

#53 in Oslo

#168 in Norway

#56,119 in the World

Oslo, NO
Oslo, Norway
Forward Citations = 206

13 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gemvax as. Retrieved from https://idiyas.com/company/gemvax-as

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…